Clinical trials recruiting for EGFR Uncommon Mutations
Fewer than 3 recruiting trials found.
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Firmonertinib | 2 |
| Definitive Thoracic Radiotherapy | 1 |
| EGFR-TKI inhibitor based on investigator's choice | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 1 |
| Colorado | 1 |
| Illinois | 1 |
| Michigan | 1 |
| New York | 1 |
| Ohio | 1 |
| Pennsylvania | 1 |
| Texas | 1 |
| Virginia | 1 |
| Washington | 1 |
Top cities
Self-screener
Recruiting trials
- Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
- Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Related conditions
Trials recruiting for EGFR Uncommon Mutations often also study these conditions. Each links to its own recruiting-trial list.
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for EGFR Uncommon Mutations trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.